TMCnet News

Hyperalgesia - Global Clinical Trials Review, H2, 2017 - Research and Markets
[November 06, 2017]

Hyperalgesia - Global Clinical Trials Review, H2, 2017 - Research and Markets


The "Hyperalgesia Global Clinical Trials Review, H2, 2017" clinical trials has been added to Research and Markets' offering.

The clinical trial report provides an overview of Hyperalgesia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperalgesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope of the Report:

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7, Trial Status, Trial Phase, Sponsor Type and End point status.
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment.
  • The report provides enrollment trends for the past five years.
  • Report provides latest news for the past three months.



Reasons to Buy:

  • Assists in formulating key business strategies with regards to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Companies Mentioned


  • Aros Pharma ApS
  • Curtin University
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Dr. Kade Pharmazeutische Fabrik (News - Alert) GmbH
  • Charleston Laboratories Inc
  • AstraZeneca Plc
  • Allergan Plc
  • Air Liquide SA
  • Abide Therapeutics Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/pgp28p/hyperalgesia


[ Back To TMCnet.com's Homepage ]